Financial News

PITTSBURGH — Mylan experienced a slight dip in sales in its third quarter, due primarily to fluctuating currency values, the generic drug maker said Thursday.

DUBLIN, Ohio — Cardinal Health had sales of $24.5 billion and profits of $339 million in first quarter 2014, the company said.

The results, announced Thursday, respectively represented a 5% decrease and 25% increase over first quarter 2013.

BURLINGTON, Mass. — A division of inVentiv Health has acquired Catalina Marketing's medication adherence services subsidiary, inVentiv said Thursday.

The acquisition of Catalina Health by Adheris makes Adheris the largest provider in the nation of tailored, direct-to-patient medication adherence programs, inVentiv said. Catalina Health president Renee Selman will lead the combined company. Financial terms of the deal were not disclosed.

NEW YORK — Jim Cramer, host of CNBC's "Mad Money," is still bullish on Rite Aid.

In a segment of "Mad Money Lightning Round" Monday evening, Cramer said of Rite Aid's stock, "I want you to stick with it. They're making a big comeback."

Indeed, the Camp Hill, Pa.-based retail pharmacy chain's stock has been shooting up lately, trading at about $5.26 per share at midday Wednesday after opening at $5.20.

PALO ALTO, Calif. — The Paws Pet Co. is buying an Irvine, Calif.-based compounding pharmacy as it seeks to transition from a pet company into a pharmaceutical company, Paws said.

HOFFMAN ESTATES, Ill. — A selloff of several store leases and the spinoff of two business segments are on the way for Sears Holdings as the company hopes to improve its third quarter 2013 performance, the retailer said Tuesday.

The company, which owns the Kmart mass-merchandise and Sears department store chains, said it would sell five store leases in Canada to Cadillac Fairview for about $383.5 million. That deal is expected to close in the next 10 business days.

DUBLIN — Actavis had sales of $2.01 billion in third quarter 2013, a 57% increase over the same period last year, the drug maker said Tuesday.

Profits for the quarter were $65.5 million, down from $76.7 million in third quarter 2012. The quarter's results exclude figures from Ireland-based Warner Chilcott, which Actavis acquired at the beginning of the month.

GURGAON, India — Ranbaxy Labs had global sales of $447.6 million in third quarter 2013, compared with $434.6 million in third quarter 2012, the Indian drug maker said Tuesday.

Sales from generics were $208.4 million, while branded and OTC drugs had sales of $239.3 million North American sales were $143.24 million including $128.6 million in the United States, lower than in Q3 2012 due to a large contribution last year from new generic drugs.